Cero Therapeutics Holdings, Inc.

CERO

Exchange: OTC
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001870404

SEC filings (opens in a new tab)

No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesCEROW

Q2 2022 vs. Q1 2022

How the institutions holding Cero Therapeutics Holdings, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022 All holders in Q1 2022

13F holders of CERO: Q1 2022 compared with Q2 2022
Measure	Q1 2022	Q2 2022	Change
Holders	45	54	+9
Shares	13.7M	14.4M	+703.9K (+5.1%)
Value	$137.2M	$144.5M	+$7.35M (+5.4%)

New holders (14)

Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to CERO in Q2 2022
Institution	Shares	Value	% of portfolio
Westchester Capital Management, LLC	461,268	$4.63M	0.14%
Vivaldi Asset Management, LLC	352,600	$3.53M	0.25%
HSBC Holdings PLC	261,723	$2.62M	0.00%
Cubist Systematic Strategies, LLC	239,920	$2.40M	0.02%
UBS Oconnor LLC	210,009	$2.11M	0.02%
Sage Rock Capital Management LP	183,998	$1.84M	0.36%
Janus Henderson Group PLC	130,000	$1.30M	0.00%
Kim, LLC	100,000	$1.00M	0.05%
Centiva Capital, LP	42,046	$422.0K	0.02%
Magnetar Financial LLC	41,100	$412.0K	0.00%
Crestline Management, LP	25,000	$251.0K	0.03%
Robinson Capital Management, LLC	6,530	$65.0K	0.05%
UBS Group AG	600	$6.00K	0.00%
Tower Research Capital LLC (TRC)	216	$2.00K	0.00%

Sold out (5)

Institutions that held Cero Therapeutics Holdings, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of CERO in Q2 2022
Institution	Shares, Q1 2022	Value, Q1 2022
Beryl Capital Management LLC	1,230,264	$12.3M
Citadel Advisors LLC	750,000	$7.50M
Spring Creek Capital LLC	100,000	$1.00M
Old Mission Capital LLC	15,188	$152.0K
Ancora Advisors, LLC	5,000	$50.0K